Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

AZD 6244 5trametinib 2pirfenidone 2Imatinib Mesylate 2tipifarnib 1peginterferon alfa-2b 1mirdametinib 1cediranib 1cabozantinib 1binimetinib 1Vinblastine 1Methotrexate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibroma, Plexiform × Everolimus × Clear all
NCT01365468 2016-05-12

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Novartis

Phase 2 Terminated
9 enrolled 8 charts
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡